# **Product Data Sheet**

### Brilliant Violet 750™ anti-human CD80

Catalog # / 2126235 / 25 tests

Size: 2126240 / 100 tests

Clone: 2D10

Isotype: Mouse IgG1, κ Reactivity: Human, Other

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 750™ under optimal

conditions.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

BSA (origin USA)

Workshop Number: VI CD80.1

Concentration: Lot-specific



Human B-cell Burkitt's lymphoma cell line Raji was stained with CD80 (clone 2D10) Brilliant Violet 750™ (filled histogram) or mouse IgG1, κ Brilliant Violet 750™ isotype control (open histogram).

## **Applications:**

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μL per million cells in 100 μL staining volume or 5  $\mu$ L per 100  $\mu$ L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 750<sup>™</sup> excites at 405 nm and emits at 750 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 750<sup>™</sup> is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application** Notes:

Additional reported applications (for the relevant formats) include: in vitro blocking of T cell activation, immunohistochemical staining of acetone-fixed frozen tissue sections<sup>2</sup>, immunoprecipitation, and Western blotting<sup>3</sup>.

#### **Application** References:

- 1. Kishimoto T, et al. Eds. 1997. Leucocyte Typing VI. Garland Publishing Inc. London.
- 2. Battifora M. 1998. J. Clin. Endocr. Metab. 83:4130. (IHC)
- 3. Van der Merwe PA, et al. 1997. J. Exp. Med. 185:3. (WB)
- 4. Jayakumar A, et al. 2008. Infect. Immun. 76:2138. PubMed
- 5. Schubert DA, et al. 2012. J. Exp Med. 209:335. PubMed
- 6. Wen T, et al. 2014. J Immunol. 192:5481. PubMed

#### **Description:**

CD80, also known as B7-1, B7, and BB1, is a 60 kD single chain type I glycoprotein belonging to the immunoglobulin superfamily. CD80 is expressed on activated B and T cells, macrophages, and dendritic cells. CD80 binds to CD28 and CD152 (CTLA-4). Along with CD86, CD80 plays a critical role in regulation of T cell activation. The interaction of CD80 with CD28 provides a potent costimulatory signal for T cell activation through the CD3 complex, while its interaction with CTLA-4 provides an inhibitory signal for T cell activation.

#### **Antigen References:**

- 1. Freeman G, et al. 1991. J. Exp. Med. 174:625.
- 2. Linsley P, et al. 1996. Immunity 4:535.
- 3. Linsley P, et al. 1991. J. Exp. Med. 174:561.